Gilead Sciences, Inc. GILD today announced that the Japanese
Ministry of Health, Labour and Welfare (MHLW) has approved Harvoni® (ledipasvir
90 mg/sofosbuvir 400 mg), the first once-daily single tablet regimen for
the treatment of chronic hepatitis C genotype 1 infection in adults.
Harvoni combines the NS5A inhibitor ledipasvir with the nucleotide
analog polymerase inhibitor sofosbuvir, approved by the MHLW under the
trade name Sovaldi® in March 2015. Harvoni is indicated for
the suppression of viremia in patients with genotype 1 chronic hepatitis
C virus (HCV) infection with or without compensated cirrhosis, with a
treatment duration of 12 weeks.
"Today's approval significantly advances the standard of care for
chronic hepatitis C in Japan, as
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in